Nehal J. Lakhani, MD, PhD Midwest, Principal Investigators, United States / Joel E In The Press Publications News & Blog Nehal J. Lakhani, MD, PhD Read More »
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101) Leave a Comment / Publication / Joel E A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101) Read More »
First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors Leave a Comment / Publication / Joel E First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors Read More »
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study Leave a Comment / Publication / Joel E Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study Read More »
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors Leave a Comment / Publication / Joel E First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors Read More »
First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers Leave a Comment / Publication / Joel E First-in human, First-in-class Phase I Trial of the Anti-CD47 Antibody Hu5F9 G4 in Patients with Advanced Cancers Read More »
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol Leave a Comment / Publication / Joel E Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent,2-methoxyestradiol Read More »